- TheStreet.com•17 hours ago
You have to keep up with the sector rotations.
- Market Realist•20 hours ago
Pfizer was trading at a forward PE multiple of ~13.0x on February 23, 2017, compared to the industry average of ~16.1x.
- Business Wire•20 hours agoIn First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects
Merck , known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company’s investigational inactivated varicella zoster virus vaccine for the prevention of herpes zoster or HZ, also known as shingles, in immunocompromised patients.
MRK : Summary for Merck & Company, Inc. (new) - Yahoo Finance
Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||65.90 x 100|
|Ask||66.14 x 200|
|Day's Range||65.63 - 66.16|
|52 Week Range||50.09 - 66.16|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||32.43|
|Dividend & Yield||1.88 (2.85%)|
|1y Target Est||N/A|